Health Economics Digest

How Medical Science Liaisons Can Transition to Health Outcomes Liaisons

Yanis Saradjin — Wed, 12 Sep 2012 18:56:27 +0000

Health economics and outcomes research (HEOR) is arguably more clinical or medical in nature than other market access-related functions. As a result, many companies now locate HEOR under medical affairs, away from the more commercially oriented pricing and reimbursement functions.

The post How Medical Science Liaisons Can Transition to Health Outcomes Liaisons appeared first on Health Economics Digest.

Co-Dependent Technologies, Market Access and Value Communication

Paul Mernagh — Wed, 05 Sep 2012 14:09:10 +0000

The Market Access world outside Australia may not have noticed yet, but there are some major changes ahead regarding how we approach health technology assessment and market access in general. As high-cost pharmaceuticals continue to face an environment of ever-tightening budget constraints, there is compounding pressure on payers to have confidence that decisions to fund [...]

The post Co-Dependent Technologies, Market Access and Value Communication appeared first on Health Economics Digest.

Personalized Medicine in the Age of Health Technology Assessments

Jordan Hinahara — Wed, 08 Aug 2012 09:25:43 +0000

US and EU Perspectives on the Value of Diagnostics - Organizations In the United States have performed these evaluations for years, and comparative effectiveness research is starting to gain traction in the UK public sector.

The post Personalized Medicine in the Age of Health Technology Assessments appeared first on Health Economics Digest.

Pharma’s Changing Business Model: The Curious Case of Pharmaceutical Price Discrimination

Community Manager — Thu, 02 Aug 2012 13:57:21 +0000

The recent fiscal chaos in Europe may have claimed another (potential) causality: the pharmaceutical industry’s ability to price discriminate between different markets on the continent.

The post Pharma’s Changing Business Model: The Curious Case of Pharmaceutical Price Discrimination appeared first on Health Economics Digest.

The Escalating Race for Evidence in Drug Reimbursement: Price Versus Value

Community Manager — Wed, 25 Jul 2012 14:58:23 +0000

While the recent acquisition spree of Walgreens, a pharmacy chain in the US, seems only tangentially related to the increasing competition for evidence in drug reimbursement, a deeper connection exists.

The post The Escalating Race for Evidence in Drug Reimbursement: Price Versus Value appeared first on Health Economics Digest.